GSK and Online Communities Create Unique Alliance to Stimulate Open Source Drug Discovery for Malaria

• GSK becomes first company to freely share chemical structures on 13,500 molecules from its compound library

• Alliances formed with leading scientific research communities from private industry and public-domain data provider

World Congress on Osteoporosis highlights changing face of bone health

Datamonitor attended this year's International Osteoporosis Foundation World Congress on Osteoporosis and 10th European Congress on Clinical and Economical Aspects of Osteoporosis and Osteoarthritis, the most important meeting on the osteoporosis calendar. A number of major pharmaceutical firms had a presence at the meeting, indicating the significance of this market.

Innovative Strategic Approaches: Moving Forward in Combating Diabetes Mellitus Among GCC countries

Researches estimate that, 366 million people - 4.4% of the world's population will be diabetic by 2030. In order to discuss the possible national and international strategies to overturn this trend - International Diabetes Summit will take place from 5th to 6th October in Dubai, UAE.

International Diabetes Summit

Date: 5th -6th October 2010
Venue: Dubai, UAE

The human and economic costs of this epidemic are enormous, diabetes increases the risk for heart disease and other health problems, and therefore it is important to give this disease more attention.

Targeting Nerve Growth Factor for Pain Therapy - Groundbreaking class to breathe new life into saturated market

Pain treatment is a multibillion dollar market that is saturated with a wide variety of branded and generic drugs. The NGF class has potential to be first of an entirely new type of painkiller to enter the sector in decades. Nevertheless, high expectations need to be tempered once the long term side effects, safety and pharmacoeconomics have been established.

Fibromyalgia - Regulatory caution threatens EU market expansion

Until regulatory hurdles in the EU are overcome, the US offers the greatest commercial potential and will be the primary growth market for all current and future brands indicated for fibromyalgia. Datamonitor forecasts the fibromyalgia market to more than double in value from 2008 to total $2.5 billion by 2018 across the seven major regions.

APS 2010: fibromyalgia newcomer seeks differentiation while prospective player draws nearer

Established drugs such as Cymbalta and Lyrica will serve to restrict uptake of the most recent entrant to the fibromyalgia market, Savella. Accordingly, data presented at this year's American Pain Society Annual Meeting indicate that Savella's marketing companies are endeavoring to differentiate the product from its key competitors in order to maintain uptake and drive sales.

NicOx: FDA panel's negative opinion casts future of osteoarthritis drug into doubt

The FDA advisory committee has issued a negative recommendation for NicOx's naproxcinod. An FDA advisory meeting has voted 16 to one against recommending the potential osteoarthritis drug naproxcinod. The decision comes after the panel found insufficient safety data to support the drug's target indication. While naproxcinod's commercial potential is now uncertain, Datamonitor believes that the announcement further highlights the FDA's enhanced scrutiny of safety in the post-Vioxx era.

SFE 2010: Selling value with customer-centric strategies

eyeforpharma's SFE 2010, April 27-29, Barcelona was an undisputed success. With over 560 attendees and more than 50 industry leaders including Jane Griffiths (IVP, Janssen Cilag), Charlotte Sibley (SVP, Shire) Javed Alam (VP Sales, Novartis) offering keen insights on all of the latest trends and challenges, it's no wonder 92% of this year's delegates said they would recommend the conference to a friend.

Prostate Cancer - Molecular targeted therapies will fulfill unmet needs in castration-resistant disease

Incidence of prostate cancer in the seven major markets will be just over 422,000 in 2009, indicating high patient potential for drug developers to invest in. There are currently 136 agents in development for prostate cancer, two-thirds of which are novel targeted therapies or immunotherapies. Collectively, the nine drugs in late-phase development are forecast to achieve $2,780m in sales by 2018.

Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies

No therapeutic cancer vaccine has received approval in any of the seven major pharmaceutical markets, despite extensive research efforts. However, with one product in pre-registration in the US, the prospect of the first marketed therapeutic cancer vaccine in the seven major markets is now closer to reality.

Dendreon: landmark cancer vaccine approval but high costs may hinder uptake

Having been approved by the FDA in castration-resistant prostate cancer, Dendreon's Provenge represents the first therapeutic cancer vaccine to reach the market. This is a significant step forward: the current standard of care is Taxotere-based chemotherapy, which is associated with significant toxicity. However, it remains to be seen how frequently Provenge is used.

Affordable On-Demand software for regulatory affairs professionals

Biopharma World

1 - 2 November, 2010
Fairmont, Singapore

The global biopharmaceutical industry is currently experiencing exponential growth with substantial opportunities to establish relationships and presence in emerging and existing markets. Major global drug companies are increasingly turning to biotechnology for new products to fuel growth.

Hepatitis C - High unmet need drives rapid innovation

The Hepatitis C market was worth $2.3 billion in 2007, declining at a CAGR of -2.8% from 2004-2007. Despite this recent slump, Datamonitor forecasts sales to grow to $4.5 billion by 2017, driven primarily by the launch of the new protease inhibitors. The US and EU will remain the largest markets, generating $1.9 billion and $1.7 billion respectively in 2017.

Hepatitis B & C in Asia - Tapping the opportunity of high prevalence rates in China, Taiwan, South Korea and Turkey

China, Taiwan, South Korea and Turkey represent highly endemic areas for viral Hepatitis. For this report, 180 high-prescribing physicians where surveyed in these countries, providing a breakdown of numbers of treated patients and the most frequently prescribed regimens.

EASL 2010: promising developments in the hepatitis C pipeline

The limitations of the current standard of care for hepatitis C virus infection have left significant room for the development of novel agents, and consequently the pipeline is highly active. Data from studies investigating the use of these agents in hepatitis C-infected patients were a key focus point at this year's European Association of the Study of the Liver meeting.

The PHARM Connect Congress 2011

The PHARM Connect Congress 2011 offers the perfect setting for solution providers to present their products and services directly to key decision makers of target client population throughout Central & Eastern Europe.